{"filings":[{"id":2409516,"accession_number":"0001140361-26-034016","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2026-08-21T20:06:02+00:00","items":["5.02"],"status":"ready","headline":"Nu Skin EVP & President of Global Sales Justin Keisel begins medical leave","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Justin Keisel, EVP and President of Global Sales, began medical leave effective Aug 17, 2026.","Chayce Clark, EVP/COO/Chief Legal Officer, will lead Keisel's organization during his absence.","Company says it wishes Keisel and family best as he focuses on health; no return date given."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2162602,"accession_number":"0001140361-26-032025","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2026-08-10T20:15:38+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q2 revenue down 17% to $320M; GAAP EPS -$5.14, adjusted $0.20","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $320.1M, down 17.1% YoY; FX impact -$4.0M.","GAAP EPS $(5.14) incl. impairment/tax charges; adjusted EPS $0.20 vs $0.43 prior.","Customers 660,037 (-14%), paid affiliates 120,291 (-8%), sales leaders 26,998 (-9%).","Q3 guide: revenue $310-340M, adjusted EPS $0.10-$0.20; FY26 revenue $1.28-1.35B, adjusted EPS $0.70-$0.90.","Dividend payments $2.9M; stock repurchases $0; $137.3M authorization remaining."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":746518,"accession_number":"0001140361-26-023312","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2026-05-29T20:05:27+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Nu Skin shareholders approve amended 2024 omnibus incentive plan with 2.85M share increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved Amended and Restated 2024 Omnibus Incentive Plan, increasing share reserve by 2,850,000 to 4,859,919 shares.","Plan termination date extended to May 28, 2036, ten years from effective date of May 28, 2026.","Voting results: 24,185,333 for, 10,177,825 against, 40,483 abstain, 5,430,258 broker non-votes.","All nine director nominees elected; advisory say-on-pay approved; PricewaterhouseCoopers ratified as auditor for 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90643,"accession_number":"0001140361-26-020028","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nu Skin EVP & Chief Product Officer Hatchett resigns effective May 8","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven K. Hatchett resigns as EVP and Chief Product Officer due to family health circumstances.","Hatchett will stay as a strategic product advisor with $147,478 annual salary.","No replacement for Chief Product Officer announced.","Effective date of resignation is May 8, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90642,"accession_number":"0001140361-26-019586","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q1 revenue $320.6M (-12% YoY), EPS $0.04; guides FY rev $1.35-1.50B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $320.6M, -12% YoY (1.1% FX tailwind); GAAP EPS $0.04, adjusted EPS $0.14 vs $0.23 prior.","Customers 669,535 (-14%), paid affiliates 120,850 (-8%), sales leaders 26,915 (-13%).","Q2 rev guidance $330-360M (-15% to -7%); EPS $0.15-0.25. FY rev $1.35-1.50B; EPS $0.70-1.10.","Returned $8M to shareholders: $2.9M dividends, $5.0M buybacks; $137.3M remaining in authorization.","Refinanced debt to extend liquidity; investing in Prysm iO platform and India launch expected late 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":320608000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100338,"accession_number":"0001140361-26-011757","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Nu Skin closes $175M term loan and $75M revolver in credit refinancing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$175M term loan fully drawn to repay existing credit agreement; $75M revolving facility also available.","Five-year maturity; interest is Term SOFR plus initial spread of 1.75% or base rate plus 0.75%.","Covenants require consolidated leverage ratio ≤2.25x and interest coverage ratio ≥3.00x.","Obligations guaranteed by material domestic subsidiaries and secured by capital stock of those subsidiaries.","Bank of America serves as administrative agent; HSBC, KeyBank, Zions, Bangkok Bank, Citibank also lenders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100337,"accession_number":"0001140361-26-010559","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nu Skin CFO James Thomas resigns; Chelsea Lantz named Interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Thomas resigned as EVP and CFO effective March 17, 2026, to pursue an outside opportunity.","Chelsea Lantz, previously VP and Corporate Controller, appointed Interim CFO effective March 18.","Lantz will earn $300,000 annual salary, 35% target bonus, plus $25,000 quarterly stipend.","Board initiated search for permanent CFO, considering both internal and external candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100336,"accession_number":"0001140361-26-008469","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nu Skin appoints Chayce Clark as COO; retains CLO role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Clark appointed EVP, COO & CLO effective March 5, 2026; will oversee global ops, sales, product innovation, tech, brand, and legal.","Base salary $650k, target bonus 75% of salary; 2026 equity award $2,362,500 (50% RSUs, 50% PRSUs).","RSUs vest 25% annually 2027–2030; PRSUs vest in three tranches based on 2026, 2027, 2028 EPS.","Clark joined Nu Skin in 2015; previously EVP & General Counsel. No family relationships or reportable transactions.","CEO cites Prysm iO platform rollout and India expansion as key growth opportunities under Clark's leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100335,"accession_number":"0001140361-26-005018","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q4 revenue $370.3M (-16.9% YoY); FY2025 EPS $3.18, adj. $1.27; Q1 2026 outlook weak","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $370.3M, down 16.9% YoY; EPS $0.29 vs $(0.73) prior year.","FY2025 revenue $1.49B (-14.3%); EPS $3.18 (incl. Mavely gain), adjusted EPS $1.27 vs $0.84 prior.","Q1 2026 guidance: revenue $320-340M, EPS $0.10-0.20; full year 2026 revenue $1.35-1.50B, EPS $0.80-1.20.","Customers 748,796 (-10%), paid affiliates 129,311 (-11%), sales leaders 30,045 (-19%).","Company anticipates return to revenue growth by year-end 2026; 20,000+ Prysm iO devices deployed."],"consensus_eps_estimate":null,"consensus_eps_actual":3.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":1485159000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116673,"accession_number":"0001140361-25-040790","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q3 revenue $364.2M (-15.3% YoY); EPS $0.34 in line with guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $364.2M, down 15.3% YoY (down 11.5% ex-Mavely); EPS $0.34 vs $0.17 prior year.","Customers 746,256 (-10%), Paid Affiliates 130,096 (-13%), Sales Leaders 31,150 (-19% YoY).","Gross margin improved to 70.5% from 70.1%; Nu Skin business gross margin 77.7% vs 76.5%.","Q4 2025 revenue outlook $365-400M, EPS $0.25-0.35; FY 2025 revenue $1.48-1.51B, EPS $3.15-3.25.","Preparing for limited Prysm iO launch and pre-market opening in India; paid $3.0M dividends, $5.0M buybacks."],"consensus_eps_estimate":null,"consensus_eps_actual":2.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":1114839000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133118,"accession_number":"0001140361-25-029613","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q2 EPS $0.43 beats guidance; raises FY EPS outlook to $3.05-$3.25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $386.1M, down 12% YoY; EPS $0.43 (adj. $0.21) vs ($2.38) prior year.","Operating margin 8.0% (vs (28.6)%); positive net cash position achieved for first time in >4 years.","Customers 771K (-14%), Sales Leaders 29.6K (-23%), Paid Affiliates 130.8K (-16%).","Rhyz Manufacturing segment +17% YoY; Latin America revenue +107% YoY.","FY 2025 guidance narrowed: rev $1.48-$1.55B; EPS raised to $3.05-$3.25 (adj. $1.15-$1.35)."],"consensus_eps_estimate":null,"consensus_eps_actual":2.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":750628000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149718,"accession_number":"0001140361-25-020939","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Nu Skin stockholders approve amended 2024 incentive plan with 790k additional shares and extension to 2035","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Amended and Restated 2024 Omnibus Incentive Plan, increasing share authorization by 790,000 shares (30,535,949 for, 1,899,631 against).","Plan termination date extended to May 29, 2035; clarifies performance cash awards not subject to minimum vesting.","All nine director nominees elected; advisory vote on executive compensation passed with ~93% support (30,210,716 for, 825,311 against).","Ratification of PricewaterhouseCoopers as independent auditor for 2025 passed with 38,374,875 for versus 492,904 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149717,"accession_number":"0001140361-25-017961","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q1 revenue $364.5M at high end of guidance; adj EPS $0.23 excl. Mavely gain","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $364.5M (-12.7% YoY, ~3% FX headwind); GAAP EPS $2.14 includes $176.2M Mavely gain; adjusted EPS $0.23.","Customers 776,712 (-11%), paid affiliates 131,518 (-15%), sales leaders 31,036 (-20%).","Reduced debt by $155M, lowest in 10+ years; returned $8M to shareholders ($3M dividends, $5M buybacks).","Q2 outlook: rev $355-390M, EPS $0.20-0.30; FY2025 rev $1.48-1.62B, adj EPS $0.90-1.30.","New product Prysm iO intelligent wellness device preview in H2 2025; India market pre-opening Q4 2025, launch mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":2.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":364490000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168750,"accession_number":"0001140361-25-007278","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nu Skin director Zheqing (Simon) Shen will not stand for re-election at 2025 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shen informed the company on March 5, 2025, of his decision due to other professional commitments.","The board thanked Shen for his contributions and years of service.","No replacement director has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168749,"accession_number":"0001140361-25-004320","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q4 revenue $445.6M, beat guidance; full-year 2025 revenue outlook $1.48-1.62B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP EPS $(0.73); adjusted EPS $0.38 vs $0.37 prior year; revenue down 8.8% YoY.","Full-year 2024 revenue $1.73B (-12%); GAAP EPS $(2.95), adjusted $0.84 vs $1.85.","Rhyz segment Q4 revenue $83.1M (+27.7%); CEO cites improving trends but China/S Korea headwinds.","Q1 2025 guidance: revenue $345-365M, EPS $2.65-2.75 (incl Mavely gain) or $0.10-0.20 ex gain.","Full-year 2025 revenue outlook $1.48-1.62B; adjusted EPS ex-Mavely gain $0.90-1.30."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":1732084000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168748,"accession_number":"0001140361-25-000867","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q4 prelim revenue at high end of guidance; closed Mavely deal for $250M","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q4 2024 preliminary revenue at high end of company's guidance range.","Recently closed strategic transaction of Mavely for $250 million.","Full Q4 and FY2024 results to be announced on Feb. 13, 2025.","CEO Ryan Napierski and CFO James Thomas to present at ICR Conference on Jan. 14."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":1732084000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168747,"accession_number":"0001140361-25-000113","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"Nu Skin sells Mavely to Later for $250M; expects ~$207M cash, $10M stock after distributions","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration $230M cash plus $20M in Purchaser common stock; closed January 2, 2025.","Nu Skin expects to retain ~$207M cash and $10M stock after payments to other Mavely equity holders.","Transaction generated ~5x return on Nu Skin's cumulative investment in Mavely since 2021 acquisition.","Proceeds to be used for debt reduction, innovation, and share repurchases under existing program.","Mavely to continue providing technology and social commerce capabilities to Nu Skin's affiliate marketing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185877,"accession_number":"0001140361-24-045667","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q3 revenue $430.1M (-13.8% YoY), EPS $0.17; guides lower Q4/FY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $430.1M (-13.8% YoY); customers 831,768 (-15%), paid affiliates 149,264 (-20%).","GAAP EPS $0.17 vs $(0.74); adjusted EPS $0.56 excluding prior-year inventory write-off.","Rhyz segment revenue $73.1M, up 20.9% YoY, partially offsetting Nu Skin core weakness.","Q4 guidance: rev $410-445M, non-GAAP EPS $0.19-0.29; FY24 rev $1.70-1.73B, non-GAAP EPS $0.65-0.75.","Cost-efficiency program: saved $15M in Q3, on track for $45-65M in 2024; cash from ops $31.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":1286532000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185876,"accession_number":"0001140361-24-045001","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Nu Skin adopts amended bylaws updating stockholder proposal and nomination procedures","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved Sixth Amended and Restated Bylaws effective Oct 31, 2024.","Clarifies nominee limit equals number of directors to be elected at meeting.","Requires stockholder nominees to submit D&O questionnaire and disclosure of compensation arrangements.","Permits company to request additional info on independence, background, and experience of nominees.","Updates procedural requirements for special meetings and information supplementation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202439,"accession_number":"0001140361-24-040955","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nu Skin appoints Mark A. Zorko to board; Audit and Nominating committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark A. Zorko appointed as director effective September 10, 2024, increasing board to nine members.","Zorko will serve on Audit Committee and Nominating and Corporate Governance Committee.","Cash retainer and annual equity award pro-rated to 75% due to mid-year appointment.","Expected to enter standard indemnification agreement; no related-party transactions reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202438,"accession_number":"0001140361-24-036406","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q2 revenue $439M, GAAP EPS $(2.38) on $141M impairment charge; guides FY24 revenue $1.73-1.81B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $439.1M, down 12.2% YoY; FX headwind of 4.2% ($21.0M).","GAAP EPS $(2.38) vs $0.54 prior-year; adjusted EPS $0.21 excluding restructuring and impairment charges.","Recorded $141M non-cash goodwill and intangibles impairment charge due to stock price decline.","Rhyz segment revenue $67.8M (+32.3% YoY); core Nu Skin customers down 14% to 893,514.","Q3 2024 revenue guidance $430-$465M; FY2024 revenue narrowed to $1.73-$1.81B, adjusted EPS $0.75-$0.95."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":856387000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218572,"accession_number":"0001140361-24-029122","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Nu Skin stockholders approve 2024 Omnibus Incentive Plan, elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved the 2024 Omnibus Incentive Plan, authorizing 1,219,919 new shares plus prior plan carryover.","All eight director nominees elected with over 35M votes for each; no significant opposition.","Advisory vote on executive compensation passed with 36.99M for vs 1.42M against.","Ratification of PricewaterhouseCoopers as independent auditor for 2024 passed with 41.57M for.","Plan effective June 5, 2024, expires June 5, 2034, replaces 2010 plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218571,"accession_number":"0001140361-24-024942","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q1 revenue $417.3M, down 13%; EPS $(0.01) GAAP; customer base shrinks 19%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $417.3M, down 13.3% YoY; foreign currency hit of $18.2M; Rhyz revenue up 57.5% to $62.5M.","GAAP EPS $(0.01); adjusted EPS $0.09 ex-restructuring vs $0.37 prior year; gross margin 70.5%.","Customers 875,261 (-19%); paid affiliates 154,171 (-30%); sales leaders 38,609 (-12%).","Q2 2024 guidance: revenue $420-455M, EPS $0.01-0.10 GAAP; 2024 full-year revenue $1.73-1.87B.","CEO cites macro headwinds; cost management supported earnings; India opening expected next year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":417306000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238470,"accession_number":"0001140361-24-013913","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Andrew Lipman to retire from Nu Skin board, will not seek re-election at 2024 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Lipman informed Nu Skin on March 15, 2024 of his decision to retire from the Board.","He will not stand for re-election at the 2024 Annual Meeting of Stockholders.","Company and Board extended gratitude for his years of service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238469,"accession_number":"0001140361-24-007981","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Nu Skin Q4 rev $488.6M (-6%), adj EPS $0.37; CSO departs; FY guide $1.73-1.87B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $488.6M (-6% YoY), adj EPS $0.37 vs $0.89; reported EPS $0.15.","FY2023 revenue $1.97B (-12%); adj EPS $1.85 after inventory write-off charges.","FY2024 guidance: rev $1.73-1.87B, adj EPS $0.95-1.35; Q1 rev $400-435M, adj EPS $0.00-0.10.","Quarterly dividend set at $0.06/share; record Feb 26, payable Mar 6, 2024.","CSO Joseph Chang departs Mar 30; will transition to Scientific Advisory Board; role no longer executive."],"consensus_eps_estimate":null,"consensus_eps_actual":0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":1969131000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238468,"accession_number":"0001140361-24-005870","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Nu Skin adopts amended bylaws aligning with Delaware law and updating stockholder meeting procedures","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Bylaws amended to align with current DGCL provisions and certificate of incorporation.","Updated advance notice deadlines and proxy solicitation rules for stockholder meetings.","Directors must submit irrevocable resignation to stand for re-election under majority voting policy.","Enhanced disclosure requirements for stockholder nominations and proposals.","Clarified advancement of expenses for former directors/officers with repayment undertaking."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238467,"accession_number":"0001140361-24-001196","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q4 preliminary revenue slightly above guidance; to present at ICR Conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q4 2023 revenue slightly above guidance range; driven by ageLOC WellSpa iO launch, China promotions, and Rhyz performance.","President & CEO Ryan Napierski and CFO James D. Thomas to present at ICR Conference on Jan. 9 at 2:30 p.m. ET.","Full Q4 and full-year 2023 results to be released on Feb. 14 after market close; conference call at 5 p.m. ET.","Webcast replay available through Jan. 23 and Feb. 28 respectively."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255979,"accession_number":"0001140361-23-050854","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["2.02","2.05","5.02","9.01"],"status":"ready","headline":"Nu Skin Q3 revenue down 7% to $498.8M; GAAP EPS $(0.74); guides FY23 revenue $1.92-1.96B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $498.8M vs $537.8M prior; GAAP EPS loss $(0.74) including $65.7M inventory write-off.","Non-GAAP EPS $0.56; customers 978,907 (-21%), paid affiliates 186,162 (-23%).","Q4 outlook revenue $440-480M, EPS $(0.14)-$0.01 or $0.15-$0.30 non-GAAP; full-year EPS $1.62-$1.77 non-GAAP.","Restructuring program with $15-25M severance charges in Q4 2023, expected completion by H1 2024.","EVP Connie Tang resigns effective Oct 31, 2023, remains advisor through April 2024; CEO overseeing her org."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":1480491000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273374,"accession_number":"0001140361-23-037383","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q2 revenue $500.3M, down 11% YoY; EPS $0.54; acquires BeautyBio","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $500.3M, -11% YoY; EPS $0.54 vs $0.67 prior year (or $0.77 ex-Grow Tech charges).","Customers 1,041,118 (-25%); Paid Affiliates 187,652 (-23%) with 13% from eligibility change.","Rhyz segment revenue up 33% YoY; announces acquisition of BeautyBio, a clean skincare and beauty device brand.","Q3 2023 guidance: revenue $500-540M, EPS $0.54-0.69; Full year revenue $2.00-2.08B, EPS $2.15-2.45.","Gross margin 72.9% (vs 73.6%); operating margin 8.5% (vs 9.2%); $175.4M remaining in buyback authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":981719000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273373,"accession_number":"0001140361-23-036542","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2023-07-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nu Skin appoints James D. Thomas as permanent CFO, replaces interim role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James D. Thomas named Executive VP and CFO effective July 24, 2023; previously served as Interim CFO since March 2023.","Annual salary set at $450,000 with 75% target bonus; granted $250,000 in RSUs and $250,000 in PRSUs.","Thomas joined Nu Skin in 2010, served as Chief Accounting Officer since 2019, and led M&A and margin improvement projects.","Appointment follows a search including internal and external candidates; no family relationships or related-person transactions reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290330,"accession_number":"0001140361-23-028959","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nu Skin stockholders elect all nine director nominees and approve say-on-pay at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected; Battle received 42.4M for, Woodbury 42.7M for.","Advisory vote on executive compensation passed with 42.4M for, 0.5M against.","Ratification of PricewaterhouseCoopers as auditor approved: 44.8M for, 0.8M against.","Future advisory votes on executive compensation set to annual (38.7M votes for 1-year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290329,"accession_number":"0001140361-23-022716","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q1 2023 revenue $481.5M (-20% YoY), EPS $0.23 vs $0.76; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue fell 20% to $481.5M; GAAP EPS $0.23 declined from $0.76; adjusted EPS $0.37 ex restructuring.","Customers down 18% to 1.08M; paid affiliates -12% to 221,354; sales leaders -17% to 43,755.","Q1 operating margin 3.3% (5.4% ex-items); recognized $9.8M restructuring and impairment charges.","Q2 2023 guidance: revenue $485-525M, EPS $0.45-$0.55. FY revenue $2.03-2.18B, EPS $2.27-2.67.","Paid $19.4M in dividends; $175.4M remaining in stock repurchase authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":481462000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311227,"accession_number":"0001140361-23-014845","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nu Skin CFO Mark Lawrence resigns; James Thomas named Interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Lawrence resigns as EVP and CFO effective March 31, 2023; will remain as senior advisor through April.","James Thomas, SVP and CAO, appointed Interim CFO effective upon Lawrence's departure.","Thomas to earn $400k salary, 50% target bonus, and $250k RSUs vesting over two years.","Company to conduct search for permanent CFO, considering internal and external candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311226,"accession_number":"0001140361-23-007254","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2023-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q4 revenue down 22% to $522.3M; guides Q1 rev $450-490M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $522.3M (-22% YoY); full-year $2.23B (-17%); customers fell 16% to 1.15M.","Q4 GAAP EPS $1.15 vs $(0.18) prior year; adjusted EPS $0.89 vs $1.11.","Full-year GAAP EPS $2.07; adjusted $2.90 vs $4.14 prior year.","Q1 2023 guidance: rev $450-490M, GAAP EPS $0.17-0.27 (non-GAAP $0.25-0.35).","FY 2023 guidance: rev $2.03-2.18B, GAAP EPS $2.27-2.67 (non-GAAP $2.35-2.75)."],"consensus_eps_estimate":null,"consensus_eps_actual":2.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":2225659000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329837,"accession_number":"0001140361-22-046688","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2022-12-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nu Skin grants $2.5M RSUs to EVP/GC Chayce Clark; salary to rise to $550k","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Compensation Committee approved $2,500,000 in restricted stock units to Chayce D. Clark on Dec. 20, 2022.","Committee anticipates increasing Clark's salary to $550,000 in Q1 2023.","Annual equity incentive award value expected to increase to approximately $1,500,000.","Clark serves as Executive Vice President and General Counsel of Nu Skin Enterprises."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329836,"accession_number":"0001140361-22-039595","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q3 2022 revenue $537.8M (-16% YoY); GAAP EPS $(0.51), non-GAAP $0.47","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $537.8M, down 16% YoY (7% FX headwind); gross margin 67.7% (72.7% ex-restructuring).","GAAP diluted EPS $(0.51) vs $0.97; non-GAAP EPS $0.47 vs $0.97.","Customers 1.24M (-11%), paid affiliates 243k (-11%), sales leaders 49.8k (-22%).","Q4 2022 guidance: revenue $500-550M (18-26% decline), EPS $0.30-0.50 ($0.40-0.60 non-GAAP).","Full-year 2022 revenue guidance $2.20-2.25B (16-18% decline); EPS $1.25-1.45 ($2.40-2.60 non-GAAP)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":1703319000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347419,"accession_number":"0001140361-22-028206","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q2 revenue falls 20% to $560.6M; cuts FY guidance, plans restructuring","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $560.6M, down 20% YoY; adjusted EPS of $0.77 (ex. Grow Tech) vs $1.15 prior year.","Paid affiliates fell 16% to 242,133; sales leaders down 24% to 50,085; customers down 6%.","FY 2022 guidance cut: revenue $2.33-2.41B (down 14-11%); adjusted EPS $3.30-$3.60.","Plans H2 restructuring with $35-45M charges; targets ~$100M cost savings in 2023.","U.S. segment posted 9th consecutive quarter of growth; SE Asia/Pac and HK/Taiwan grew on ageLOC Meta."],"consensus_eps_estimate":null,"consensus_eps_actual":1.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":1165514000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347418,"accession_number":"0001140361-22-025598","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2022-07-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin prelim Q2 revenue $557-562M, soft due to China COVID, EMEA conflict","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Estimated Q2 2022 revenue between $557 and $562 million, softer than expected.","COVID-related extended lockdowns in Mainland China and Russia-Ukraine conflict weighed on results.","Growth in Southeast Asia and ongoing U.S. momentum partially offset headwinds.","Company launches ageLOC LumiSpa iO connected beauty device, expects sequential H2 improvements.","Full Q2 results and revised guidance to be released on Aug. 4, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":1.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":1165514000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363864,"accession_number":"0001140361-22-023342","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Nu Skin enters into $900M credit facility; $400M term loan + $500M revolver, 5-year term","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New credit agreement provides a $400M term loan and a $500M revolving credit facility, each with a five-year term.","On June 14, 2022, the Company drew the full term loan ($400M) and $30M on the revolver to repay all amounts outstanding under its prior credit agreement.","Loans bear interest at Term SOFR plus an initial spread of 1.75% (term) or 2.00% (revolver), adjustable based on leverage ratio.","Financial covenants require a consolidated leverage ratio ≤2.75x and interest coverage ratio ≥3.00x.","The credit agreement includes customary events of default and restrictions on liens, indebtedness, investments, and dividends."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363863,"accession_number":"0001140361-22-021884","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2022-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nu Skin stockholders elect nine directors, approve executive compensation, ratify auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected; votes for ranged from 37.3M (Lipman) to 40.9M (Shen), with ~3.0M broker non-votes.","Advisory vote on executive compensation approved: 40.5M for, 0.4M against, 0.15M abstain, 3.0M broker non-votes.","Ratification of PricewaterhouseCoopers as independent auditor for FY2022 approved: 42.7M for, 1.3M against, 37K abstain.","Meeting held June 2, 2022; results filed June 6, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363862,"accession_number":"0001140361-22-021546","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2022-06-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nu Skin EVP Connie Tang takes temporary medical leave; CEO to lead her organization","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Connie Tang, EVP and Chief Global Growth and Customer Experience Officer, begins medical leave May 31, 2022.","Leave expected to last approximately three months for recovery from a medical procedure.","President and CEO Ryan Napierski will directly lead Tang's organization during her absence.","Tang notified the company of her decision on May 27, 2022.","Company expresses support for Tang's recovery and anticipates her return."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363861,"accession_number":"0001140361-22-017649","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q1 revenue $604.9M (-11% YoY), EPS $0.76 (-16%); lowers FY22 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $604.9M, down 11% YoY; EPS $0.76 vs $0.91; gross margin 73.3% vs 74.8%.","Customers fell 13% to 1.32M; paid affiliates -14%; sales leaders -22%.","Q2 revenue guidance $590-620M (down 12-16%); EPS $0.75-0.85 (down 26-35%).","Full-year 2022 revenue guidance cut to $2.51-2.62B (down 3-7%); EPS $3.60-3.90.","Declines blamed on COVID lockdowns in China, Ukraine/Russia conflict, FX headwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":604899000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363860,"accession_number":"0001140361-22-014934","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2022-04-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nu Skin reports 2021 adjusted EPS up 14% to $4.14; revenue up 4%; unveils Nu Vision 2025 plan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue increased 4% in 2021; adjusted EPS grew 14% to $4.14 (reported EPS down 21% to $2.86 due to restructuring).","U.S. business grew 32% reflecting social commerce adoption; new product launches: Beauty Focus Collagen+ and ageLOC Meta.","Nu Vision 2025 targets high single/low double-digit growth, 13% operating margin, and social commerce >50% of global business by 2025.","Incurred $51.9M restructuring and impairment charge and $6.7M inventory write-off in 2021.","EmpowerMe strategy uses IoT devices for personalized beauty/wellness; new apps Vera and Stela support affiliates and customers."],"consensus_eps_estimate":null,"consensus_eps_actual":0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":604899000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383605,"accession_number":"0001140361-22-005670","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2022-02-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q4 rev $673M (-10%), adj EPS $1.11; FY22 guidance rev $2.66-2.77B, EPS $4.05-4.45","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $673.4M, down 10% YoY; customers down 12% to 1.37M, sales leaders down 13% to 61,515.","Adjusted EPS (excl. restructuring/impairment) $1.11 vs $1.40; GAAP EPS $(0.18) due to $58.5M Grow Tech exit charge.","Full-year 2021 revenue $2.70B (+4% YoY); adjusted EPS $4.14 vs $3.63.","Q1 2022 guidance: rev $560-590M, EPS $0.65-0.75; FY22 rev $2.66-2.77B, EPS $4.05-4.45.","Introduced Nu Vision 2025 strategy focused on personalized beauty/wellness and affiliate social commerce."],"consensus_eps_estimate":null,"consensus_eps_actual":2.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":2695669000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383604,"accession_number":"0001140361-22-000661","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2022-01-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nu Skin CEO Ryan Napierski outlines Nu Vision 2025 strategy in New Year message","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["CEO emphasizes EmpowerME personalized beauty/wellness and IoT devices to disrupt $1.2T beauty & wellness market.","Company aims to capitalize on social commerce growth from $585B (2021) to $3.4T by 2028.","New digital ecosystem includes Vera (personalized insights) and Stela (affiliate tools) apps.","Reaffirms goal to become world's leading integrated beauty and wellness company via digital-first affiliate model.","Message covers strategy but provides no updated financial guidance or material operational changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":401430,"accession_number":"0001140361-21-043301","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2021-12-29T23:59:59+00:00","items":["2.05","2.06"],"status":"ready","headline":"Nu Skin to exit Grow Tech segment, expects $52-60M in pre-tax charges","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Decision to wind down controlled-environment agriculture business, focused on feed industry.","Non-cash charges: ~$18M goodwill/intangibles, ~$14M fixed assets, ~$7M inventory write-down.","Cash charges: ~$7M severance and $10-18M contract termination/legal costs.","Substantially all non-cash and severance charges expected in Q4 2021; remainder later.","Charges not reflected in prior 2021 Q4 or full-year financial guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":401429,"accession_number":"0001140361-21-036423","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2021-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q3 revenue $641.2M (-9% YoY), EPS $0.97 (-10%); cuts Q4 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $641.2M, down 9% YoY; EPS $0.97 vs $1.08 in prior year.","Sales leaders down 15% to 58,565; customers down 9% to 1,395,271.","U.S. growth driven by Beauty Focus Collagen+ launch; Korea double-digit growth.","Q4 revenue guidance $645-675M (-10 to -14% YoY); EPS $0.90-1.00.","2021 full-year revenue guided $2.67-2.70B (+3-5%); EPS $3.93-4.03 (+8-11%)."],"consensus_eps_estimate":null,"consensus_eps_actual":3.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":2022233000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":401428,"accession_number":"0001140361-21-033451","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2021-10-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin estimates Q3 revenue $637-642M, below expectations due to delta variant disruptions","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Estimated Q3 2021 revenue between $637M and $642M, softer than anticipated.","Delta variant caused unexpected disruptions, especially in Mainland China and Southeast Asia, impacting sales and promotions.","U.S. Collagen+ launch drove strong growth; Tencent digital tools introduced in China during the quarter.","Full Q3 results and revised 2021 guidance to be announced on November 3, 2021.","Annual 2021 revenue expected to be up modestly year over year, management remains confident in strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":3.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":2022233000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420385,"accession_number":"0001140361-21-027549","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K/A","filed_at":"2021-08-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nu Skin appoints Ryan Napierski as CEO; compensation package disclosed: $900K salary, RSUs, PSOs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Ryan Napierski's annual salary set at $900,000 effective Sept 1, 2021.","Target bonus now 110% of salary; RSU grant valued at ~$700,000 vesting over 4 years.","PSOs valued at ~$1,050,000 vest in two tranches based on 2022 and 2023 EPS.","Anticipated annual equity incentive increase to ~$3,350,000 in 2022.","Napierski covered under existing Executive Severance Policy with CEO-specific payments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420386,"accession_number":"0001140361-21-026910","cik":1021561,"company_name":"NU SKIN ENTERPRISES, INC.","ticker":"NUS","form_type":"8-K","filed_at":"2021-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nu Skin Q2 revenue $704.1M, EPS $1.15 (+42% YoY), raises FY EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $704.1M (+15% YoY, +6% FX); EPS $1.15 vs $0.81 prior year (+42%).","Operating margin improved 260 bps to 12.1% on expense control and supply chain efficiency.","Sales leaders up 15% to 64,228; customers down 2% to 1.47M due to prior-year surge.","Q3 guidance: rev $700-730M, EPS $1.10-1.20; FY21 guidance raised to rev $2.81-2.87B, EPS $4.30-4.50.","President Ryan Napierski noted ageLOC Boost launch in EMEA and upcoming Beauty Focus Collagen+ and ageLOC Meta."],"consensus_eps_estimate":null,"consensus_eps_actual":2.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":1381081000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":292274272.67232597,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-08-04T23:59:59+00:00|420386"}